GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antibe Therapeutics Inc (STU:4B70) » Definitions » Cyclically Adjusted PB Ratio

Antibe Therapeutics (STU:4B70) Cyclically Adjusted PB Ratio : 1.48 (As of Jun. 23, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Antibe Therapeutics Cyclically Adjusted PB Ratio?

As of today (2024-06-23), Antibe Therapeutics's current share price is €2.44. Antibe Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was €1.65. Antibe Therapeutics's Cyclically Adjusted PB Ratio for today is 1.48.

The historical rank and industry rank for Antibe Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:4B70' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 1.84
Current: 0.46

During the past years, Antibe Therapeutics's highest Cyclically Adjusted PB Ratio was 1.84. The lowest was 0.00. And the median was 0.00.

STU:4B70's Cyclically Adjusted PB Ratio is not ranked
in the Biotechnology industry.
Industry Median: 1.66 vs STU:4B70: 0.46

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Antibe Therapeutics's adjusted book value per share data for the three months ended in Dec. 2023 was €0.337. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €1.65 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Antibe Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Antibe Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antibe Therapeutics Cyclically Adjusted PB Ratio Chart

Antibe Therapeutics Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 1.47 0.97

Antibe Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.81 0.97 0.73 0.77 1.46

Competitive Comparison of Antibe Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Antibe Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Antibe Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Antibe Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Antibe Therapeutics's Cyclically Adjusted PB Ratio falls into.



Antibe Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Antibe Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=2.44/1.65
=1.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Antibe Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Antibe Therapeutics's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.337/125.0724*125.0724
=0.337

Current CPI (Dec. 2023) = 125.0724.

Antibe Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201403 0.618 98.604 0.784
201406 0.535 99.473 0.673
201409 0.334 99.394 0.420
201412 0.179 98.367 0.228
201503 0.067 99.789 0.084
201506 0.167 100.500 0.208
201509 0.064 100.421 0.080
201512 0.450 99.947 0.563
201603 0.343 101.054 0.425
201606 0.382 102.002 0.468
201609 0.302 101.765 0.371
201612 0.331 101.449 0.408
201703 0.220 102.634 0.268
201706 0.242 103.029 0.294
201709 0.202 103.345 0.244
201712 0.133 103.345 0.161
201803 0.252 105.004 0.300
201806 0.243 105.557 0.288
201809 0.196 105.636 0.232
201812 0.169 105.399 0.201
201903 0.202 106.979 0.236
201906 0.146 107.690 0.170
201909 0.227 107.611 0.264
201912 0.168 107.769 0.195
202003 0.083 107.927 0.096
202006 0.523 108.401 0.603
202009 0.377 108.164 0.436
202012 0.280 108.559 0.323
202103 0.735 110.298 0.833
202106 0.944 111.720 1.057
202109 0.836 112.905 0.926
202112 0.816 113.774 0.897
202203 0.782 117.646 0.831
202206 0.738 120.806 0.764
202209 0.679 120.648 0.704
202212 0.573 120.964 0.592
202303 0.521 122.702 0.531
202306 0.459 124.203 0.462
202309 0.391 125.230 0.391
202312 0.337 125.072 0.337

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Antibe Therapeutics  (STU:4B70) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Antibe Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Antibe Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Antibe Therapeutics (STU:4B70) Business Description

Traded in Other Exchanges
N/A
Address
15 Prince Arthur Avenue, Toronto, ON, CAN, M5R 1B2
Antibe Therapeutics Inc is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The company's pipeline includes assets that seek to overcome gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs. Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for post-operative pain. Antibe's second pipeline drug, ATB-352, is being developed for a specialized acute pain indication. The company's anticipated next target is inflammatory bowel disease, a condition long in need of safer, more effective therapies.

Antibe Therapeutics (STU:4B70) Headlines

No Headlines